Page 1087 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 60 Myelodysplastic Syndromes 969.e1

REFERENCES 25. Ma X, Does M, Raza A, et al: Myelodysplastic syndromes: incidence
and survival in the United States. Cancer 109(8):1536–1542, 2007.
1. Steensma DP: Historical perspectives on myelodysplastic syndromes. 26. Cogle CR, Iannacone MR, Yu D, et al: High rate of uncaptured
Leuk Res 36:1441, 2012. myelodysplastic syndrome cases and an improved method of case
2. Luzzatto A: Sull’ anemia grave megaloblastica senza reporto ematologico ascertainment. Leuk Res 38(1):71–75, 2014.
corrispondente (anemia pseudoaplastica). Riv veneta di sc med Venezia 27. Cogle CR, Craig BM, Rollison DE, et al: Incidence of the myelodys-
47:193–212, 1907. plastic syndromes using a novel claims-based algorithm: high number of
3. Guglielmo G: di Eritremie acute. BollettinoSocieta Medico Chir uncaptured cases by cancer registries. Blood 117(26):7121–7125, 2011.
1:665–673, 1926. 28. Pavlu J, Emmerson J, Marks AJ, et al: Idiopathic cytopenia of
4. Rhoads C, Barker W: Refractory anemia: analysis of 100 cases. JAMA undetermined significance and the minimal criteria for a diagnosis of
110:794–796, 1938. myelodysplastic syndrome. Leuk Lymphoma 52(3):515–516, 2011.
5. Rosati S, Mick R, Xu F, et al: Refractory cytopenia with multilineage 29. Sekeres MA, Schoonen WM, Kantarjian H, et al: Characteristics of US
dysplasia: further characterization of an “unclassifiable” myelodysplastic patients with myelodysplastic syndromes: results of six cross-sectional
syndrome. Leukemia 10(1):20–26, 1996. physician surveys. J Natl Cancer Inst 100(21):1542–1551, 2008.
6. Chevallier P: Sur la terminologie des leucoses et les affections-frontieres: 30. Marisavljevic D, Savic A, Zeremski V, et al: Myelodysplastic syndromes
les odoleucoses. Sangre (Barc) 15:587–593, 1942. in adults aged less than 50 years: incidence and clinicopathological data.
7. Hamilton-Paterson J: Pre-leukaemic anaemia. Acta Haematol 2:309– J BUON 19(4):999–1005, 2014.
316, 1949. 31. Jaiswal S, Fontanillas P, Flannick J, et al: Age-related clonal hematopoiesis
8. Block M, Jacobson LO, Bethard WF: Preleukemic acute human associated with adverse outcomes. N Engl J Med 371(26):2488–2498,
leukemia. J Am Med Assoc 152(11):1018–1028, 1953. 2014.
9. Saarni MI, Linman JW: Preleukemia. The hematologic syndrome 32. Genovese G, Kähler AK, Handsaker RE, et al: Clonal Hematopoiesis
preceding acute leukemia. Am J Med 55(1):38–48, 1973. and Blood-Cancer Risk Inferred from Blood DNA Sequence. N Engl J
10. Dreyfus B, Rochant H, Sultan C, et al: Refractory anemia with Med 371(26):2477–2487, 2014.
excess myeloblasts in the bone marrow. Study of 11 cases]. Presse Med 33. Stary J, Baumann I, Creutzig U, et al: Getting the numbers straight
78(8):359–364, 1970. in pediatric MDS: distribution of subtypes after exclusion of down
11. Dreyfus B: Preleukemic states. I. Definition and classification. II. syndrome. Pediatr Blood Cancer 50(2):435–436, 2008.
Refractory anemia with an excess of myeloblasts in the bone marrow 34. Germing U, Aul C, Niemeyer CM, et al: Epidemiology, classification
(smoldering acute leukemia). Nouv Rev Fr Hematol Blood Cells and prognosis of adults and children with myelodysplastic syndromes.
17(1–2):33–55, 1976. Ann Hematol 87(9):691–699, 2008.
12. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the clas- 35. Lange BJ, Kobrinsky N, Barnard DR, et al: Distinctive demography,
sification of the acute leukaemias. French-American-British (FAB) biology, and outcome of acute myeloid leukemia and myelodysplastic
co-operative group. Br J Haematol 33(4):451–458, 1976. syndrome in children with Down syndrome: Children’s Cancer Group
13. Galton D, Dacie J: Classification of the acute leukaemias. Blood Cells Studies 2861 and 2891. Blood 91(2):608–615, 1998.
1:17–24, 1975. 36. Butturini A, Gale RP, Verlander PC, et al: Hematologic abnormalities
14. Linman JW: Myelomonocytic leukemia and its preleukemic phase. J in Fanconi anemia: an International Fanconi Anemia Registry study.
Chronic Dis 22(11):713–716, 1970. Blood 84(5):1650–1655, 1994.
15. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classifica- 37. Hahn CN, Chong C-E, Carmichael CL, et al: Heritable GATA2
tion of the myelodysplastic syndromes. Br J Haematol 51(2):189–199, mutations associated with familial myelodysplastic syndrome and acute
1982. myeloid leukemia. Nat Genet 43(10):1012–1017, 2011.
16. Cabello AI, Collado R, Ruiz MA, et al: A retrospective analysis of 38. Owen CJ, Toze CL, Koochin A, et al: Five new pedigrees with inherited
myelodysplastic syndromes with thrombocytosis: reclassification of the RUNX1 mutations causing familial platelet disorder with propensity to
cases by WHO proposals. Leuk Res 29(4):365–370, 2005. myeloid malignancy. Blood 112(12):4639–4645, 2008.
17. Voglová J, Chrobák L, Neuwirtová R, et al: Myelodysplastic and 39. Zhang MY, Churpek JE, Keel SB, et al: Germline ETV6 mutations
myeloproliferative type of chronic myelomonocytic leukemia–distinct in familial thrombocytopenia and hematologic malignancy. Nat Genet
subgroups or two stages of the same disease? Leuk Res 25(6):493–499, 47(2):180–185, 2015.
2001. 40. Yamaguchi H, Baerlocher GM, Lansdorp PM, et al: Mutations of the
18. Giagounidis AA, Germing U, Haase S, et al: Clinical, morphological, human telomerase RNA gene (TERC) in aplastic anemia and myelo-
cytogenetic, and prognostic features of patients with myelodysplastic dysplastic syndrome. Blood 102(3):916–918, 2003.
syndromes and del(5q) including band q31. Leukemia 18(1):113–119, 41. Surveillance, Epidemiology, and End Results Program.html [Internet].
2004. [cited 2015 Feb 25];Available from: <http://seer.cancer.gov/>.
19. Hasserjian RP, Campigotto F, Klepeis V, et al: De novo acute myeloid 42. Komrokji RS, Padron E, Ebert BL, et al: Deletion 5q MDS: molecular
leukemia with 20-29% blasts is less aggressive than acute myeloid and therapeutic implications. Best Pract Res Clin Haematol 26(4):365–
leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology 375, 2013.
Group study. Am J Hematol 89(11):E193–E199, 2014. 43. Yin SN, Hayes RB, Linet MS, et al: A cohort study of cancer among
20. Valent P, Bain BJ, Bennett JM, et al: Idiopathic cytopenia of unde- benzene-exposed workers in China: overall results. Am J Ind Med
termined significance (ICUS) and idiopathic dysplasia of uncertain 29(3):227–235, 1996.
significance (IDUS), and their distinction from low risk MDS. Leuk 44. Tong H, Hu C, Yin X, et al: A Meta-analysis of the relationship between
Res 36(1):1–5, 2012. cigarette smoking and incidence of myelodysplastic syndromes. PLoS
21. Riccardi A, Giordano M, Girino M, et al: Refractory cytopenias: ONE 8(6):e67537, 2013.
clinical course according to bone marrow cytology and cellularity. Blut 45. Chen B, Zhao W-L, Jin J, et al: Clinical and cytogenetic features of
54(3):153–163, 1987. 508 Chinese patients with myelodysplastic syndrome and comparison
22. Della Porta MG, Travaglino E, Boveri E, et al: Minimal morpho- with those in Western countries. Leukemia 19(5):767–775, 2005.
logical criteria for defining bone marrow dysplasia: a basis for clinical 46. Gologan R, Georgescu D, Tatic A, et al: Epidemiological data from the
implementation of WHO classification of myelodysplastic syndromes. registry of patients with myelodysplastic syndrome in a single hospital
Leukemia 29(1):66–75, 2015. center of Romania. Leuk Res 33(11):1556–1561, 2009.
23. Sekeres MA: The epidemiology of myelodysplastic syndromes. Hematol 47. Matsuda A, Germing U, Jinnai I, et al: Difference in clinical features
Oncol Clin North Am 24(2):287–294, 2010. between Japanese and German patients with refractory anemia in
24. Craig BM, Rollison DE, List AF, et al: Underreporting of myeloid myelodysplastic syndromes. Blood 106(8):2633–2640, 2005.
malignancies by United States cancer registries. Cancer Epidemiol 48. Iwanaga M, Hsu W-L, Soda M, et al: Risk of myelodysplastic syn-
Biomark Prev 21(3):474–481, 2012. dromes in people exposed to ionizing radiation: a retrospective cohort